The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of
clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).
Both modes of action work together to manage
the clinical signs of congestive heart failure (CHF).4, 5
To determine whether chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical myxomatous mitral valve disease (MMVD) can delay the onset of
clinical signs of congestive heart failure (CHF).1
The most common
clinical sign of congestive heart failure (CHF) is persistent coughing accompanied by difficulty breathing.
Not exact matches
The QUEST Study established pimobendan as the new standard
of treatment for dogs with
congestive heart failure (CHF) caused by MMVD as it extended survival time.2 The veterinary community also sought to answer this question: Can pimobendan also delay the onset
of clinical signs of CHF?
The
clinical phase was designed to span 3 years and follow dogs to the primary endpoint (onset
of clinical signs caused by left ‑ sided
congestive heart failure or cardiac ‑ related death).
Additionally, the
clinical signs associated with the development
of atrial fibrillation (that is,
congestive heart failure) resolve when the rate is controlled.
The addition
of Enalapril or Benazapril to conventional therapy in dogs with chronic
congestive heart failure resulted in a significant decrease in
clinical signs and a 92 % increase in survival time.
Dr. Jones said he would like to see further investigation into the pathology
of heartworm infection, particularly into why the disease manifests in various
clinical signs in dogs, which can have coughing, lung inflammation, or
congestive heart failure, or why they can have no
clinical signs at all.
There is very weak veterinary
clinical and experimental evidence based upon a limited number
of studies to indicate that adding transdermal nitroglycerine to other therapies used for management
of left - sided
congestive heart failure in dogs speeds the resolution
of clinical signs.
A diagnosis
of complete AV block with
clinical signs of right sided
congestive heart failure was made and pacemaker implantation was decided.
A diagnosis
of an intra atrial mass with
clinical signs of a progressing left sided
congestive heart failure was made and a surgery was discussed.
The majority
of patients with the disease will not progress to developing
congestive heart failure (CHF) and will have no
clinical signs and live an otherwise normal life.